Revista de Senologia y Patologia Mamaria最新文献

{"title":"Discrepancy of PD1/ PD-L1 status between primary and metastatic triple negative breast cancer in diagnostic biopsies","authors":"Manar Moustafa,&nbsp;Basma Hamed Ibrahim","doi":"10.1016/j.senol.2025.100680","DOIUrl":"10.1016/j.senol.2025.100680","url":null,"abstract":"<div><h3>Introduction</h3><div>The evaluation of programmed death protein-ligand 1 (PD-L1) in triple-negative breast cancer (TNBC) has become routine for accurate decisions regarding immune checkpoint therapy. The aim of our paper was to analyze whether the PD-L1 evaluated in biopsy specimens accurately reflects its expression in the whole tumor and paired metastases in TNBC.</div></div><div><h3>Methods</h3><div>Immunohistochemistry was applied on 66 biopsy and resection specimens from TNBC cases and matched metastasis to determine PD-L1 status. PD-L1 was evaluated using 4 scoring methods immune cell (IC) and tumor cell (TC) with a 1% as the cutoff value, and combined positive scores (CPSs) with a 1% and 10% as the cutoff value.</div></div><div><h3>Results</h3><div>A total of 66 TNBC patients show a statistically significant PDL1 IC positive expression with unfavorable prognostic factors. PD-L1 was positive in IC more than TC in biopsy specimen and in surgical specimen. The overall concordance between biopsies and surgical specimens at IC score was 55.2%, at CPS 1% it was 65.2%, and at CPS 10 it was 68.2%. The pooled discordance rate varied according to the cells that expressed PD-L1: A total of 37.9% of cases had discordant primary/metastatic PD-L1 status when it was assessed on immune cells, 31.8% when it was assessed on tumor cells, and 28.8% when it was assessed by CPS &gt; 10%</div></div><div><h3>Conclusions</h3><div>Misclassifying TNBC patients as PD-L1-negative at biopsy can lead to disqualification from anti-PD-L1 therapy. PD-L1 status conversion occurs frequently between primary tumor and metastases, emphasizing the need for multiple biopsies, adequate tissue sampling, additional tests, and standardization in immunotherapy selection.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100680"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cáncer de mama en mujeres mayores de 80 años: tratamiento primario","authors":"Leyre Marco Sanz,&nbsp;Sara del Olmo Bautista,&nbsp;Henar Sánchez Quirós,&nbsp;Yolanda Pérez Martínez,&nbsp;Sergio Gutiérrez García,&nbsp;Verónica Palomo Cabañes,&nbsp;Marta Robles Gaitero,&nbsp;María Purificación Martínez del Val,&nbsp;Teodora Alonso Gutiérrez,&nbsp;Modesto Rey Novoa","doi":"10.1016/j.senol.2025.100666","DOIUrl":"10.1016/j.senol.2025.100666","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objetivo&lt;/h3&gt;&lt;div&gt;analizar el tipo de tratamiento primario que reciben pacientes mayores de 80 años en un intervalo de 6 años.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material y método&lt;/h3&gt;&lt;div&gt;se ha realizado un estudio observacional retrospectivo en pacientes mayores de 80 años diagnosticadas de cáncer de mama, de 2017 a 2022. Se recogieron datos sobre el tipo de tratamiento, cirugía, características histológicas, estadio y calidad de vida.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Resultados&lt;/h3&gt;&lt;div&gt;se obtuvieron datos de un total de 188 pacientes. Edad media de 85 años. El 38,3% eran dependientes para actividades básicas de la vida diaria. Un 73,4% presentaban positividad para receptores estrogénicos y HER2 negativo. Un 75,5% recibió cirugía como tratamiento primario, un 11,1% recibió hormonoterapia, un 3,1% tratamiento con quimioterapia y un 10,1% no recibieron ningún tipo de tratamiento. El 22,3% se encontraban en estadio I. El 13,2% fueron diagnosticadas en estadio avanzado. A un 33,5% se le realizó una biopsia selectiva de ganglio centinela (BSGC).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusiones&lt;/h3&gt;&lt;div&gt;según nuestros datos analizados, existe un considerable número de pacientes que han recibido un tratamiento primario más agresivo (mastectomía y BSGC) sin beneficios en la supervivencia general a pesar de que, actualmente, existen datos que apoyan que la omisión de la evaluación axilar quirúrgica o, incluso, la radioterapia después de cirugía conservadora, no afecta la supervivencia general en mujeres de 70 años o más con enfermedad en estadio clínico temprano, receptor hormonal positivo y HER2 negativo.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Analyzing the type of primary treatment that patients aged over 80 years receive within a 6-year interval.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and method&lt;/h3&gt;&lt;div&gt;An observational retrospective study was conducted in patients aged over 80 years who were diagnosed with breast cancer between 2017 to 2022. Data were collected on the type of primary treatment, surgery, histological characteristics of tumors, stage and quality of life.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Information was taken from 188 patients. The average age was 85 years old. A 38,3% were dependent for Basic Activities of Daily Living, 73,4% tested positive for estrogen receptors and negative HER2, 75,5% underwent surgery as primary treatment, 11,1% received hormone therapy, 3,1% received chemotherapy treatment, and 10,1% did not undergo any type of treatment; 22,3% of patients were in stage I. A 13,2% were diagnosed at an advanced stage, and 33,5% underwent selective sentinel lymph node biopsy (SSNB).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusión&lt;/h3&gt;&lt;div&gt;According to our analyzed data, there is a considerable number of patients who have undergone a more aggressive primary treatment (mastectomy and SSNB) without benefits in overall survival, despite evidence supporting that omitting surgical axillary evaluation or even radiotherapy after conservative surgery does not affect overall survival in women a","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100666"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143299284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Journal of Senology and Breast Disease. Why Transition to English?","authors":"David Martínez Ramos","doi":"10.1016/j.senol.2025.100705","DOIUrl":"10.1016/j.senol.2025.100705","url":null,"abstract":"","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100705"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal timing of sentinel node detection using [99mTc]Tc-phytate lymphoscintigraphy: A study of 100 breast cancer patients","authors":"Masoud Moslehi ,&nbsp;Mohammadreza Elhaie ,&nbsp;Koozari Abolfazl ,&nbsp;Iraj Abedi","doi":"10.1016/j.senol.2025.100682","DOIUrl":"10.1016/j.senol.2025.100682","url":null,"abstract":"<div><h3>Introduction</h3><div>Sentinel lymph node biopsy guided by preoperative lymphoscintigraphy is an established technique for axillary staging in breast cancer. However, the optimal timing for lymphoscintigraphic imaging remains unclear. Earlier acquisition may expedite surgery while later imaging improves detection rates by allowing radiotracer transit. Defining the timeframe maximizing accuracy and minimizing burden is needed.</div></div><div><h3>Objective</h3><div>To evaluate optimal acquisition timings for [99mTc]Tc-Phytate lymphoscintigraphy in sentinel lymph node mapping for breast cancer.</div></div><div><h3>Methods</h3><div>Hundred breast cancer patients underwent periareolar injection of 1–2 mCi [99mTc]Tc-Phytate and lymphoscintigraphy at 5,10, 30, 60 and 120 min post-injection. Lymph node visualization was assessed by experienced nuclear medicine physicians based on retrospective review of scintigraphy images. Descriptive statistics characterized patient demographics and time to sentinel lymph node detection. Correlation analyses evaluated relationships between visualization parameters and factors such as age, sex and surgical history.</div></div><div><h3>Results</h3><div>Lymph nodes were typically visible within 10 min (median). Regression found no significant predictors of prolonged transit time among age, sex, surgical history. Age is not a statistically significant predictor of node visualization (<em>p</em> = 0.129). Also sex and surgery history are not significant predictors of longer time (<em>p</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>Sentinel lymph node biopsy guided by lymphoscintigraphy is an important technique for axillary staging in breast cancer. Standardizing acquisition timing could optimize the accuracy and efficiency of lymphoscintigraphy for axillary staging.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100682"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tissue reaction of the hydrogel marker HydroMARK©","authors":"Francesc Tresserra,&nbsp;Jorge Perez-Fuentes,&nbsp;Carmen Ara","doi":"10.1016/j.senol.2025.100699","DOIUrl":"10.1016/j.senol.2025.100699","url":null,"abstract":"","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100699"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we use HER2DX to modulate treatment intensity in HER2 positive early breast cancer?","authors":"Beatriz Alonso De Castro ,&nbsp;Cristina Reboredo Rendo ,&nbsp;Fernanda Mosele ,&nbsp;Eva Pérez López ,&nbsp;Lourdes Calvo Martínez ,&nbsp;Silvia Antolín Novoa","doi":"10.1016/j.senol.2024.100659","DOIUrl":"10.1016/j.senol.2024.100659","url":null,"abstract":"<div><div>Clinical HER2 positive (cHER2<!--> <!-->+) breast cancer (BC) is an heterogenous disease, which represents a major challenge in the design of personalized therapeutic strategies. In recent years, a great development against HER2 targeted therapies took place, but not all patients benefit from the same regimens. In this context, it is essential to develop genomic analysis, with clinicopathological and molecular biomarkers, as HER2DX, in order to improve response, safety, and patient's quality of life. This review aims to comprehensively summarize the current evidence regarding the development, validation, and application of HER2DX score in clinical practice. Genomic development and clinical application in the identification of different cHER2<!--> <!-->+ BC populations are discussed, along as future changing strategies for escalation and de-escalation treatments.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100659"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Del Ars Magna a la inteligencia artificial generativa","authors":"Rafael Berlanga Llavori","doi":"10.1016/j.senol.2024.100663","DOIUrl":"10.1016/j.senol.2024.100663","url":null,"abstract":"<div><div>This article aims to present the key elements in the evolution of Artificial Intelligence (AI) in recent years, especially Generative Artificial Intelligence. Predictive or discriminative AI has had a notable impact on medicine in the last two decades, especially in the diagnosis of pathologies based on clinical data. Now, generative AI leads us to new challenges and opportunities in numerous fields such as personalised treatment, prevention, pro-action, new therapeutic techniques and, in general, the broadening of the horizons of clinical and biomedical research. For this work, we have carried out a bibliographic study and organised it into the main ideas for the application of generative AI to medicine. The main result of this study is a set of potential applications of generative AI that are being initiated in several areas of medicine and that may lead to a revolution in medicine in the short to mid-term. However, there are major hurdles to overcome, mainly those concerning the quality and accuracy of these systems, as well as the privacy and ethical barriers that must be respected by the new automated healthcare systems.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100663"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143132587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of 25-Hydroxyvitamin D Levels and Their Relationship with Breast Cancer Biomarkers CA15-3 and CEA: A Retrospective Study","authors":"Zineb Sakhi,&nbsp;Kawtar Nabil,&nbsp;Kaoutar Anouar Tadlaoui,&nbsp;Moulay Mustapha Ennaji","doi":"10.1016/j.senol.2025.100678","DOIUrl":"10.1016/j.senol.2025.100678","url":null,"abstract":"<div><h3>Introduction</h3><div>Vitamin D deficiency is prevalent and often overlooked, especially in countries like Morocco. Concurrently, breast cancer remains the most common cancer among women globally. Recent interest has focused on the link between vitamin D levels and breast cancer development. This study aims to examine the relationship between serum levels of breast cancer biomarkers and vitamin D status in Moroccan women, while exploring associations with clinicopathological features.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis was conducted on 116 Moroccan women. The vitamin D status and serum levels of CA15-3 and CEA were evaluated by Competitive Immunoassay Technique with End-Point Fluorescence Detection (ELFA) and Chemiluminescent Microparticle Immunoassay (CMI). Statistical analyses evaluated the associations between vitamin D status and breast cancer risk, with a particular focus on comparing CA15-3 and CEA levels between vitamin D-deficient and non-deficient patients.</div></div><div><h3>Results</h3><div>Vitamin D deficiency was significantly associated with elevated CA15-3 levels (<em>p</em> = 0.041), with all patients showing elevated CA15-3 being vitamin D deficient. However, no significant correlation was identified between vitamin D levels and CEA (<em>p</em> = 0.221). In vitamin D-deficient patients, a negative correlation was observed between vitamin D and CA15-3 levels (r = −<!--> <!-->0.244, <em>p</em> = 0.017), suggesting that lower vitamin D levels may contribute to higher CA15-3 concentrations.</div></div><div><h3>Conclusion</h3><div>Our findings highlight that a significant association was observed between CA15-3 levels (abnormal ≥<!--> <!-->30 U/mL) and vitamin D status (<em>p</em> = 0.041), but the logistic regression model did not confirm this association. This suggests that additional factors may influence this association, and further studies are needed to confirm these findings.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100678"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silent complications: Liquid silicone granuloma in a patient after unregulated cosmetic mamary augmentation","authors":"Guillermo Lillo-Albert ,&nbsp;Ernesto Muñoz-Sornosa ,&nbsp;Marcos Adrianzén-Vargas ,&nbsp;Vicente López-Flor ,&nbsp;Elvira Buch-Villa","doi":"10.1016/j.senol.2025.100701","DOIUrl":"10.1016/j.senol.2025.100701","url":null,"abstract":"","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100701"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of artificial intelligence integrating multi-omics in breast cancer","authors":"Raquel Gómez-Bravo ,&nbsp;Benjamín Walbaum ,&nbsp;Elia Segui ,&nbsp;Montserrat Muñoz","doi":"10.1016/j.senol.2025.100677","DOIUrl":"10.1016/j.senol.2025.100677","url":null,"abstract":"<div><div>In an era of precision oncology, genomic testing plays a crucial role in the management of breast cancer. A variety of complex techniques for germline, somatic, and gene expression testing are routinely used as part of our clinical practice. However, challenges remain in both interpreting genomic data and in the ever-expanding breadth of available tumor information. Artificial intelligence (AI), specifically machine learning and deep learning models, can create and facilitate the interpretation of complex genetic data, predict patient outcomes, and personalize treatment plans. Herein, we present a review of the current role of AI integrating multi-omics in BC.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100677"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}